Jose et al. report their experience treating a portopulmonary hypertension patient with the activin signalling inhibitor Sotatercept. Treatment resulted in improvement in the burden of pulmonary hypertension, as well as changes in the circulating plasma proteome and pulmonary artery circulating leukocyte transcriptome, demonstrating benefit and supporting further investigation of this therapeutic in the management of portopulmonary hypertension.
- Arun Jose
- William Zacharias
- Assem Ziady
